Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...
BioSpace10d
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
FiercePharma8d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...
Business Insider1mon
Regeneron Buy Rating Supported by Eylea HD Launch, Dupixent Expansion, and Libtayo Success
The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application ... the successful launch of Dupixent for chronic obstructive ...
Morningstar10d
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Anti-inflammatory Dupixent's sales are up 15% ... The company is planning to offer a prefilled syringe version of the drug later this year and will broaden the label to include macular edema ...
Seeking Alpha10d
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label ... of care in the anti-VEGF category. Dupixent's ongoing growth is supported by recent ...